VIDEO: Gordon Findlay, Novo Nordisk Executive, Collapses During White House Rollout of Cheaper Obesity Drugs

A White House press event on Thursday promoting efforts to lower the cost of obesity medications took an unexpected turn when a guest suddenly collapsed in the Oval Office — in front of President Donald Trump and a group of pharmaceutical executives, including Dr. Mehmet Oz, who rushed to the man’s aid.

The dramatic moment, captured on video before feeds were cut, occurred as the President and industry leaders discussed a new federal initiative to make obesity and weight-loss drugs more affordable for Americans.

“Are you OK? Gordon, you OK?”
— Eli Lilly CEO David Ricks, moments before the man fell to the floor

Witnesses said officials quickly called for the press to leave the room as the man was helped to the ground. Dr. Oz, serving as Trump’s administrator for the Centers for Medicare & Medicaid Services, immediately bent over to check his condition while the White House Medical Unit responded.

 

Gordon Findlay, Novo Nordisk Executive, Collapses During White House Rollout of Cheaper Obesity Drugs

Gordon Findlay, Novo Nordisk Executive, Collapses During White House Rollout of Cheaper Obesity Drugs

White House Press Secretary Karoline Leavitt later confirmed that the man had experienced a fainting spell and was “doing okay.”

“The White House Medical Unit quickly jumped into action, and the gentleman is okay,” Leavitt said, adding that the event resumed shortly afterward.

President Trump reassured attendees that the man had simply become “a little bit lightheaded.”

Identity Speculation and Corporate Silence

While officials did not immediately confirm the man’s identity, online speculation identified him as Gordon Findlay, the Global Brand Director for Novo Nordisk, the pharmaceutical company behind blockbuster weight-loss and diabetes drugs Ozempic, Rybelsus, and Wegovy.

Findlay, who has worked for Novo Nordisk since 2023 and is based in Basel, Switzerland, oversees several global marketing initiatives, including Norditropin and strategic brand planning. He holds a Ph.D. in Biochemistry from the University of Kent and has played a key role in the company’s growth amid soaring global demand for its weight-loss medications.

Gordon Findlay, Novo Nordisk Executive, Collapses During White House Rollout of Cheaper Obesity Drugs

When reached for comment by the New York Post, Novo Nordisk declined to confirm the identity of the individual who collapsed. A spokesperson stated that CEO Mike Doustdar and Dave Moore, EVP of U.S. Operations, were the only company representatives officially present at the White House event.

“We hope the gentleman who suffered a medical incident today is okay,” the company said in a brief statement, offering no further details.

The company has not commented on whether Findlay was present or what may have caused the medical emergency.

Broader Context: Obesity Drug Push

Thursday’s event was part of a White House initiative to expand access to obesity medications, which are increasingly recognized as critical tools in combating the country’s growing health crisis.

Obesity remains one of the leading causes of preventable death in the United States, second only to tobacco use. It contributes to a wide range of chronic conditions, including heart disease, stroke, type 2 diabetes, and several forms of cancer.

As of now, neither the White House nor Novo Nordisk has provided additional updates about the incident, leaving many to wonder whether Gordon Findlay was indeed the individual who fainted — and whether the company is trying to deflect attention from an uncomfortable moment at a politically charged event.